Compare ABEV & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABEV | TEVA |
|---|---|---|
| Founded | 1885 | 1901 |
| Country | Brazil | Israel |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1B | 40.5B |
| IPO Year | 2012 | 1996 |
| Metric | ABEV | TEVA |
|---|---|---|
| Price | $2.93 | $39.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $3.34 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 18.8M | 4.1M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.93 | N/A |
| Revenue Next Year | $4.89 | $3.91 |
| P/E Ratio | $16.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $18.83 |
| 52 Week High | $3.45 | $40.79 |
| Indicator | ABEV | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 56.77 |
| Support Level | $2.83 | $30.42 |
| Resistance Level | $3.11 | $40.79 |
| Average True Range (ATR) | 0.05 | 1.25 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 40.91 | 61.08 |
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.